Literature DB >> 28337696

Cerebral Dopamine Neurotrophic Factor: A Potential Therapeutic Agent for Parkinson's Disease.

Tingting Tang1, Yong Li1, Qian Jiao1, Xixun Du1, Hong Jiang2.   

Abstract

The application of neurotrophic factors (NTFs) is a promising therapeutic strategy for neurodegenerative disorders such as Parkinson's disease (PD). Many NTFs have been reported to enhance the survival, regeneration, and differentiation of neurons and to induce synaptic plasticity. However, because of their potential side-effects and low efficacy after clinical administration, more potent treatments for neurodegenerative disorders are being sought. Cerebral dopamine neurotrophic factor (CDNF), a newly-identified NTF homologous to mesencephalic astrocyte-derived NTF, is structurally and functionally different from other NTFs, providing new hope especially for PD patients. In various animal models of PD, CDNF is efficient in protecting and repairing dopaminergic neurons, and it inhibits endoplasmic reticulum stress, neuroinflammation, and apoptosis. Recent progress in all facets of CDNF research has enabled researchers to better understand its beneficial effects in the treatment of PD.

Entities:  

Keywords:  Anti-apoptotic; Anti-inflammatory; Cerebral dopamine neurotrophic factor; Neuroprotection; Parkinson’s disease

Mesh:

Substances:

Year:  2017        PMID: 28337696      PMCID: PMC5636730          DOI: 10.1007/s12264-017-0123-4

Source DB:  PubMed          Journal:  Neurosci Bull        ISSN: 1995-8218            Impact factor:   5.203


  72 in total

1.  Comparing neuroprotective effects of CDNF-expressing bone marrow derived mesenchymal stem cells via differing routes of administration utilizing an in vivo model of Parkinson's disease.

Authors:  Mei Jiaming; Chaoshi Niu
Journal:  Neurol Sci       Date:  2014-08-27       Impact factor: 3.307

2.  Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease.

Authors:  Ashley D Reynolds; Rebecca Banerjee; Jianou Liu; Howard E Gendelman; R Lee Mosley
Journal:  J Leukoc Biol       Date:  2007-08-03       Impact factor: 4.962

Review 3.  Mesencephalic astrocyte-derived neurotrophic factor and cerebral dopamine neurotrophic factor: New endoplasmic reticulum stress response proteins.

Authors:  Hao Liu; Xiaolei Tang; Lei Gong
Journal:  Eur J Pharmacol       Date:  2015-01-28       Impact factor: 4.432

4.  Cerebral dopamine neurotrophic factor improves long-term memory in APP/PS1 transgenic mice modeling Alzheimer's disease as well as in wild-type mice.

Authors:  Susanna Kemppainen; Päivi Lindholm; Emilia Galli; Hanna-Maija Lahtinen; Henna Koivisto; Elina Hämäläinen; Mart Saarma; Heikki Tanila
Journal:  Behav Brain Res       Date:  2015-05-11       Impact factor: 3.332

5.  The Solution Structure and Dynamics of Full-length Human Cerebral Dopamine Neurotrophic Factor and Its Neuroprotective Role against α-Synuclein Oligomers.

Authors:  Cristiane Latge; Katia M S Cabral; Guilherme A P de Oliveira; Diana P Raymundo; Julia A Freitas; Laizes Johanson; Luciana F Romão; Fernando L Palhano; Torsten Herrmann; Marcius S Almeida; Debora Foguel
Journal:  J Biol Chem       Date:  2015-07-06       Impact factor: 5.157

6.  Armet, a UPR-upregulated protein, inhibits cell proliferation and ER stress-induced cell death.

Authors:  Andria Apostolou; Yuxian Shen; Yan Liang; Jun Luo; Shengyun Fang
Journal:  Exp Cell Res       Date:  2008-05-13       Impact factor: 3.905

7.  Mesencephalic astrocyte-derived neurotrophic factor is an ischemia-inducible secreted endoplasmic reticulum stress response protein in the heart.

Authors:  Archana Tadimalla; Peter J Belmont; Donna J Thuerauf; Matthew S Glassy; Joshua J Martindale; Natalie Gude; Mark A Sussman; Christopher C Glembotski
Journal:  Circ Res       Date:  2008-10-16       Impact factor: 17.367

8.  Novel neurotrophic factor CDNF protects and rescues midbrain dopamine neurons in vivo.

Authors:  Päivi Lindholm; Merja H Voutilainen; Juha Laurén; Johan Peränen; Veli-Matti Leppänen; Jaan-Olle Andressoo; Maria Lindahl; Sanna Janhunen; Nisse Kalkkinen; Tõnis Timmusk; Raimo K Tuominen; Mart Saarma
Journal:  Nature       Date:  2007-07-05       Impact factor: 49.962

9.  Characterization of the structural and functional determinants of MANF/CDNF in Drosophila in vivo model.

Authors:  Riitta Lindström; Päivi Lindholm; Jukka Kallijärvi; Li-Ying Yu; T Petteri Piepponen; Urmas Arumäe; Mart Saarma; Tapio I Heino
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

Review 10.  Treatment Options for Urogenital Dysfunction in Parkinson's Disease.

Authors:  Amit Batla; Natalie Tayim; Mahreen Pakzad; Jalesh N Panicker
Journal:  Curr Treat Options Neurol       Date:  2016-10       Impact factor: 3.598

View more
  5 in total

1.  Biomarker Discovery in Parkinson's Disease: Present Challenges and Future Opportunities.

Authors:  Song Li; Weidong Le
Journal:  Neurosci Bull       Date:  2017-09-21       Impact factor: 5.203

Review 2.  Transcription Factors: Potential Cell Death Markers in Parkinson's Disease.

Authors:  Ronglin Wang; Shaosong Yang; Tiejian Nie; Gang Zhu; Dayun Feng; Qian Yang
Journal:  Neurosci Bull       Date:  2017-08-08       Impact factor: 5.203

3.  Identification of candidate biomarkers and pathways associated with type 1 diabetes mellitus using bioinformatics analysis.

Authors:  Madhu Pujar; Basavaraj Vastrad; Satish Kavatagimath; Chanabasayya Vastrad; Shivakumar Kotturshetti
Journal:  Sci Rep       Date:  2022-06-01       Impact factor: 4.996

4.  Association between cerebral dopamine neurotrophic factor (CDNF) 2 polymorphisms and schizophrenia susceptibility and symptoms in the Han Chinese population.

Authors:  Yongfeng Yang; Hongyan Yu; Wenqiang Li; Bing Liu; Hongxing Zhang; Shuang Ding; Yanli Lu; Tianzi Jiang; Luxian Lv
Journal:  Behav Brain Funct       Date:  2018-01-03       Impact factor: 3.759

5.  Downregulation of DmMANF in Glial Cells Results in Neurodegeneration and Affects Sleep and Lifespan in Drosophila melanogaster.

Authors:  Lucyna Walkowicz; Ewelina Kijak; Wojciech Krzeptowski; Jolanta Górska-Andrzejak; Vassilis Stratoulias; Olga Woznicka; Elzbieta Chwastek; Tapio I Heino; Elzbieta M Pyza
Journal:  Front Neurosci       Date:  2017-11-02       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.